Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Chromosome 19 Annotations… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Chromosome 19 Annotations with Disease Speciation: A First Report from the Global Research Consortium

Artikel i vetenskaplig tidskrift
Författare C. L. Nilsson
F. Berven
F. Selheim
H. L. Liu
J. R. Moskal
R. A. Kroes
E. P. Sulman
C. A. Conrad
F. F. Lang
P. E. Andren
A. Nilsson
Elisabet Carlsohn
H. Lilja
J. Malm
D. Fenyo
D. Subramaniyam
X. D. Wang
M. Gonzales-Gonzales
N. Dasilva
P. Diez
M. Fuentes
A. Vegvari
K. Sjodin
C. Welinder
T. Laurell
T. E. Fehniger
H. Lindberg
M. Rezeli
G. Edula
S. Hober
G. Marko-Varga
Publicerad i Journal of Proteome Research
Volym 12
Nummer/häfte 1
Sidor 134-149
ISSN 1535-3893
Publiceringsår 2013
Publicerad vid Core Facilities, Proteomics
Sidor 134-149
Språk en
Länkar dx.doi.org/10.1021/pr3008607
Ämnesord proteins, genes, antibodies, mRNA, mass spectrometry, bioinformatics, protein microarray, human, human proteome project, gene-expression, hybridization, guidelines, arrays
Ämneskategorier Biokemi, Genetik, Farmaceutisk biokemi, Medicinsk genetik

Sammanfattning

A first research development progress report of the Chromosome 19 Consortium with members from Sweden, Norway, Spain, United States, China and India, a part of the Chromosome-centric Human Proteome Project (C-HPP) global initiative, is presented (http://www.c-hpp.org). From the chromosome 19 peptide-targeted library constituting 6159 peptides, a pilot study was conducted using a subset with 125 isotope-labeled peptides. We applied an annotation strategy with triple quadrupole, ESI-Qtrap, and MALDI mass spectrometry platforms, comparing the quality of data within and in between these instrumental set-ups. LC–MS conditions were outlined by multiplex assay developments, followed by MRM assay developments. SRM was applied to biobank samples, quantifying kallikrein 3 (prostate specific antigen) in plasma from prostate cancer patients. The antibody production has been initiated for more than 1200 genes from the entire chromosome 19, and the progress developments are presented. We developed a dedicated transcript microarray to serve as the mRNA identifier by screening cancer cell lines. NAPPA protein arrays were built to align with the transcript data with the Chromosome 19 NAPPA chip, dedicated to 90 proteins, as the first development delivery. We have introduced an IT-infrastructure utilizing a LIMS system that serves as the key interface for the research teams to share and explore data generated within the project. The cross-site data repository will form the basis for sample processing, including biological samples as well as patient samples from national Biobanks.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?